Russ Chorush

Russell Chorush

[ partner ]

Russell Chorush

Dr. Chorush specializes in patent infringement and antitrust cases in the high technology arena. He has represented various clients in litigation in fields ranging from electronics to chemicals and focuses primarily on reverse-payment pharmaceutical cases brought under the Sherman Antitrust Act and FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013). The cases on which Dr. Chorush has worked have achieved recoveries in excess of one billion dollars and he has prevailed in each case he has tried to a final decision. Prior to his professional law practice he graduated valedictorian from the University of Houston Law Center in May 2001 and obtained the top score on the July 2001 Texas state bar examination.

While at the University of Houston Law Center, Dr. Chorush served as the Notes & Comments editor on the Houston Law Review and received the following awards: the National Burton Award for Legal Achievement, the Dean’s Scholarship, the Baker Botts Award, the West Group Outstanding Scholastic Achievement Award, the Suzanne White Booker Student Scholarship, the Locke Liddell & Sapp LLP IP and Technology Scholarship, the Hutcheson & Grundy Scholarship, the Joan Garfinkel Glantz Prize, the Griggs & Harrison Award, and the LEX Awards (top score in his law school section) in civil procedure, torts I, torts II, property II, and contracts II.

Prior to law school, Dr. Chorush served as a laboratory manager for Texas Instruments, Inc. (“TI”) and Air Liquide Corporation. He is a co-author of the book “Handbook of Chemicals and Gases for the Semiconductor Industry” as well as a number of published articles and is a named inventor on several patents assigned to TI. Dr. Chorush is an author of six published articles in peer-reviewed journals including the Journal of the American Chemical Society, Analytical Chemistry and the Journal of Mass Spectrometry. He received his Ph.D. in analytical chemistry from Cornell University in 1994 and a B.S. in chemistry from the University of Texas at Austin in 1989.

Notable Current Cases

  • In re K-Dur Antitrust Litigation, MDL Docket No. 01-MD-1419 (D.N.J) (representing plaintiffs)
  • King Drug Company of Florence, Inc. et al. v. Cephalon, Inc., et al., Civ. No. 2:06-cv-1797 (E.D. Pa.) (representing plaintiffs as to remaining defendants Mylan and Ranbaxy)
  • In re Androgel Antitrust Litigation, MDL Docket No. 1:09-MD-2084 (N.D. Ga.) (representing plaintiffs)
  • In re Aggrenox Antitrust Litigation, 3:14-md-02516 (D. Conn.) (representing plaintiffs)
  • In re Lamictal Antitrust Litigation, Case No. 2:12-cv-995 (D.N.J.) (representing plaintiffs)
  • In re Lidoderm Antitrust Litigation, Case No. 14-md-02521 (N.D. Cal.) (representing plaintiffs)
  • Burlington Drug Co., Inc. v. Pfizer Inc. et al., Civ. No. 3:12-cv-02389 (D.N.J.) (representing plaintiffs)
  • In re Niaspan Antitrust Litigation, Case No. 2:13-md-02460 (E.D. Penn.) (representing plaintiffs)
  • In re Opana ER Antitrust Litigation, MDL No. 2580, Lead Case No. 14-cv-10150 (N.D. Ill.) (representing plaintiffs)

Notable Past Cases

  • King Drug Company Of Florence, Inc. et al. v. Cephalon, Inc., et al., Civ. No. 2:06-cv-1797 (E.D. Pa.) (representing plaintiffs, which obtained a $512 million settlement as to defendants Cephalon, Barr and Teva)
  • In re Tricor Antitrust Litigation, Civ. No. 05-CV-340 (D. Del.) (represented plaintiffs, which obtained a $250 million settlement)
  • In re Buspirone Antitrust Litigation, Civ. No. 01-MDL-1410 (S.D.N.Y) (represented plaintiffs, which obtained a $220 million settlement)
  • In re Neurontin Antitrust Litigation, MDL Docket No. 02-MD-1479 (D.N.J.) (representing plaintiffs, which obtained a $190 million settlement)
  • In re Terazosin Hydrochloride Antitrust Litigation, MDL Docket No. 99-MDL-1317 (S.D. Fla.) (represented plaintiffs, which obtained a $74 million settlement)
  • In re Remeron Antitrust Litigation, Civ. No. 2:02-CV-02007 (D.N.J.) (represented plaintiffs, which obtained a $75 million settlement)
  • UniRAM Technology, Inc. v. Monolithic System Technology et al, Civ. No. 04-CV-1268 (N.D. Cal.) (represented plaintiff, which obtained a $30.5 million jury verdict, a $36 million judgment, a successful bench opinion on inequitable conduct, and a favorable confidential settlement)
  • PACT XPP Technologies, AG v. Xilinx, Inc. and Avnet, Inc., Civ. No. 2:07-cv-563 (E.D. Tex.) (represented plaintiff, which obtained a $15.4 million jury verdict, a $40.8 million judgment, and a favorable confidential settlement)
  • Rochester Drug Co-Operative, Inc. v. Braintree Laboratories, Inc., Civ. No. 07-cv-142 (D. Del.) (represented plaintiffs, which obtained a $17.25 million settlement)
  • In re Oxycontin Antitrust Litigation, MDL Docket No. 04-MDL-1603 (S.D.N.Y.) (represented plaintiffs, which obtained a $16 million settlement)
  • ROY-G-BIV Corporation v. Fanuc Ltd. et al., Civ. No. 2:07-cv-418 (E.D. Tex.) (represented plaintiffs, which obtained a favorable confidential settlement)
  • ROY-G-BIV Corporation v. ABB, Ltd. et al., Civ. No. 6:11-CV-00622 (E.D. Tex.) (representing plaintiff, which obtained a favorable confidential settlement)
  • ROY-G-BIV Corporation v. Honeywell Int’l, Inc. et al., Civ. No. 6:11-cv-623 (E.D. Tex.) (representing plaintiff, which obtained a favorable confidential settlement)
  • ROY-G-BIV Corporation v. Siemens Corporation et al., Civ. No. 6:11-CV-00624 (E.D. Tex.) (representing plaintiff, which obtained a favorable confidential settlement)

Awards & Honors

  • Super Lawyer Rising Star (Thomson-Reuters) (2005-2007, 2010-2011)
  • University of Houston Law Center Rising Star Award (2005)
  • Recipient of the highest score on the July 2001 Texas Bar Exam
  • Valedictorian of the University of Houston Law Center Class of 2001